Takeaways from the UH CINEMA Program

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

Now Viewing

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

Video content above is prompted by the following:

• Let’s discuss some initiatives we have championed at our institutions. What are these initiatives and how are they impacting the care of CRM patients? Dr. Neeland: Tell us about the University Hospitals Heart & Vascular Institute’s Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (UH CINEMA).
• How is the UH CINEMA program advancing health care for patients with overlapping heart, diabetes, and kidney issues?
• What challenges have you experienced implementing this program?
• What specific results can you share from this program?
• What are future opportunities to improve CRM care based on this program?

This activity is supported by an educational grant from Boehringer Ingelheim.